AU3927895A - Lipid-splitting enzyme - Google Patents

Lipid-splitting enzyme

Info

Publication number
AU3927895A
AU3927895A AU39278/95A AU3927895A AU3927895A AU 3927895 A AU3927895 A AU 3927895A AU 39278/95 A AU39278/95 A AU 39278/95A AU 3927895 A AU3927895 A AU 3927895A AU 3927895 A AU3927895 A AU 3927895A
Authority
AU
Australia
Prior art keywords
enzyme
substrates
disclosed
lipid
target cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU39278/95A
Other versions
AU711367B2 (en
Inventor
Dieter Herrmann
Hans-Georg Opitz
Harald Zilch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma Holding GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19518278A external-priority patent/DE19518278A1/en
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU3927895A publication Critical patent/AU3927895A/en
Assigned to ROCHE DIAGNOSTICS GMBH reassignment ROCHE DIAGNOSTICS GMBH Amend patent request/document other than specification (104) Assignors: BOEHRINGER MANNHEIM GMBH
Priority to AU44675/99A priority Critical patent/AU740293B2/en
Application granted granted Critical
Publication of AU711367B2 publication Critical patent/AU711367B2/en
Assigned to HEIDELBERG PHARMA HOLDING GMBH reassignment HEIDELBERG PHARMA HOLDING GMBH Alteration of Name(s) in Register under S187 Assignors: ROCHE DIAGNOSTICS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.
AU39278/95A 1994-11-12 1995-11-09 Lipid-splitting enzyme Ceased AU711367B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44675/99A AU740293B2 (en) 1994-11-12 1999-08-24 Lipid splitting enzyme

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4440472 1994-11-12
DE4440472 1994-11-12
DE9518278 1995-05-18
DE19518278A DE19518278A1 (en) 1994-11-12 1995-05-18 Lipid-cleaving enzyme
PCT/EP1995/004414 WO1996015234A2 (en) 1994-11-12 1995-11-09 Lipid-splitting enzyme

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU44675/99A Division AU740293B2 (en) 1994-11-12 1999-08-24 Lipid splitting enzyme

Publications (2)

Publication Number Publication Date
AU3927895A true AU3927895A (en) 1996-06-06
AU711367B2 AU711367B2 (en) 1999-10-14

Family

ID=25941931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39278/95A Ceased AU711367B2 (en) 1994-11-12 1995-11-09 Lipid-splitting enzyme

Country Status (12)

Country Link
EP (1) EP0791056B1 (en)
JP (2) JP3681005B2 (en)
AT (1) ATE292173T1 (en)
AU (1) AU711367B2 (en)
CA (1) CA2204908A1 (en)
DE (1) DE59510996D1 (en)
DK (1) DK0791056T3 (en)
ES (1) ES2239761T3 (en)
HU (1) HUT77486A (en)
NZ (1) NZ295682A (en)
PT (1) PT791056E (en)
WO (1) WO1996015234A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100471526C (en) 2000-03-31 2009-03-25 施托克赫森有限公司 Liquid absorbent layer comprising pulverulent polymers crosslinked on the surface
EP1460082A1 (en) * 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipid esters of clofarabine derivatives
WO2008052722A2 (en) * 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4026265A1 (en) * 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
DE4402492A1 (en) * 1994-01-28 1995-08-03 Boehringer Mannheim Gmbh Process for the production of asymmetrical phosphoric acid diesters

Also Published As

Publication number Publication date
ATE292173T1 (en) 2005-04-15
EP0791056B1 (en) 2005-03-30
AU711367B2 (en) 1999-10-14
CA2204908A1 (en) 1996-05-23
PT791056E (en) 2005-08-31
WO1996015234A2 (en) 1996-05-23
WO1996015234A3 (en) 1996-06-20
DK0791056T3 (en) 2005-07-04
HUT77486A (en) 1998-05-28
JP2005095178A (en) 2005-04-14
NZ295682A (en) 1999-09-29
EP0791056A2 (en) 1997-08-27
JPH10508498A (en) 1998-08-25
ES2239761T3 (en) 2005-10-01
JP3681005B2 (en) 2005-08-10
DE59510996D1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
Ortaldo et al. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes
TR199801680T2 (en) Tablets containing beta-lactam antibiotics and method of manufacture.
ATE397665T1 (en) LYMPHOTOXIN-BETA, LYMPHOTOXIN-BETA COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
ATE347585T1 (en) IN-VITRO GROWTH OF ISLANDS OF LANGERHANS AND THEIR USES
AU4718496A (en) Use of aerogels in agriculture
WO1991009958A3 (en) Method of delivering molecules into eukaryotic cells
CA2004597A1 (en) Topical formulations and transdermal delivery systems containing 1-isobutyl-1h-imidazo-[4,5-c]quinoline-4-amine
AU6821687A (en) System for delivering drug with enhanced bioacceptability
AU3927895A (en) Lipid-splitting enzyme
ES2004099A6 (en) Use of biologically active polypeptides and compositions containing them.
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
ES2145284T3 (en) DERIVATIVES OF DIOXO-TIOPIRANO-PIRIDIN-CARBOXILICO ACID AND ITS USE AS DRUGS.
AU2267892A (en) Molecular encapsulation and delivery of alkanes to living mammalian cells for risk assessment and pharmaceutical application
AU1929397A (en) Use of il-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular
DE60007074D1 (en) SULFATED PHOSPHATIDYLINOSITOLS, THEIR PRODUCTION AND USE
FI960839A0 (en) Novel tripeptides useful in immune and CNS therapy
FR2752527B1 (en) USE OF A BERTHOLLETIA EXTRACT IN THE COSMETIC OR PHARMACEUTICAL AREA, ESPECIALLY DERMATOLOGICAL, AND FOR THE PREPARATION OF CELL CULTURE MEDIA
AU6049390A (en) Protection of nk cell cytolytic activity in pbmc
Snyderman et al. Biologic aspects of leukocyte chemotaxis
NO942228L (en) Ipsapirone drug preparation
CA2086835A1 (en) Tissue plasminogen activator variants with decreased clearance
Akanji et al. Effect of repeated administration of suramin on alkaline phosphatase activity in rat kidney.
EP0136093A3 (en) Anti-cancer factors
UA5743C2 (en) Preparation of biologically active tissue substances possessing regenerative activity and method for its production
Lahat et al. Monocyte suppressor function in burns: T cell-monocyte interaction in mediating suppression

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: HEIDELBERG PHARMA HOLDING GMBH

Free format text: FORMER OWNER WAS: ROCHE DIAGNOSTICS GMBH